Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Stamer, U. M.; Lee, E. H.; Kleine‐Brueggeney, M.; Zhang, L.; Musshoff, F.; Stuber, F.
University of Bern, Department of Anaesthesiology and Pain Medicine, Bern, Switzerland
Background: An influence of polymorphic CYP2D6 genetic variants on antiemetic efficacy of ondansetron has been suggested [1,2]. However, the role of CYP3A in ondansetron metabolism has been obscure up to date. In this study the hypothesis that genotype dependent CYP2D6 and CYP3A activity selectively influences plasma concentrations of ondansetron enantiomers was evaluated. Additionally, the effects of doubling the ondansetron dose on genotype dependent plasma concentrations was investigated exploratively.
Methods: After approval of the local ethics committee and written informed consent patients scheduled for major abdominal surgery received i.v. ondansetron 4 mg (group O‐4) or 8 mg (group O‐8) for prophylaxis of PONV. CYP2D6 dependent activity score representing no, decreased, normal or increased CYP2D6 enzyme activity and CYP3A low (CYP3A5*3/*3) or high expressor status (CYP3A5*1/*1 or *1/*3) were determined by real‐time PCR. Plasma concentrations of R‐ and S‐ondansetron were measured by liquid chromatography‐tandem mass spectrometry. Areas under the time concentration curves (AUC) of R‐ and S‐ondansetron concentrations were associated to CYP2D6 and CYP3A5 genotype dependent enzyme activity.
Results: Complete data of 141 subjects could be analyzed. Concentrations of S‐ondansetron differed between CYP2D6 activity groups (p=0.04) with highest measures in patients with no CYP2D6 activity (mean (5/95% CI): 362.5 (238.3/486.7) h·ng/ml) and lowest concentrations in those with increased activity (149.6 (114.5/184.8) h·ng/ml) compared to subject displaying genotypes resulting in reduced or normal CYP2D6 activity (263.6 (228.8/298.8), 255.4 (228.2/282.7) h·ng/ml). AUC of R‐ondansetron was two‐times higher in CYP3A5 low expressors compared to high expressors: (281.5 (248.6/314.3) vs. 142.5 (92.4/192.7) h·ng/ml; p=0.009. Doubling the ondansetron dose only increased plasma concentrations in individuals with low CYP3A5 activity with no increase in individuals with high enzyme activities (p< 0.001).
Conclusions: Metabolism of ondansetron seems to be enantioselective. Genetically and environmentally determined CYP2D6 and CYP3A enzyme activity might have implications for antiemetic efficacy.
Acknowledgements: The study was supported in part by the R. Sackler Research Foundation.
© 2011 European Society of Anaesthesiology
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at European Journal of Anaesthesiology (EJA).
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics